{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T17:50:59Z","timestamp":1760205059627,"version":"build-2065373602"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.lungcan.2020.02.006","type":"journal-article","created":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T02:21:58Z","timestamp":1581646918000},"page":"47-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement"],"prefix":"10.1016","volume":"142","author":[{"given":"Giuseppe","family":"Bronte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Delmonte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco Angelo","family":"Burgio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Verlicchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Puccetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Bravaccini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Cravero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Maddalena","family":"Tumedei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danila","family":"Diano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulio","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Ulivi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucio","family":"Crin\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 5","key":"10.1016\/j.lungcan.2020.02.006_bib0005","doi-asserted-by":"crossref","first-page":"v31","DOI":"10.1093\/annonc\/mdv199","article-title":"ESMO Guidelines Committee. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Baas","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2020.02.006_bib0010","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.lungcan.2015.06.018","article-title":"Second line therapy in malignant pleural mesothelioma: a systematic review","volume":"89","author":"Buikhuisen","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2020.02.006_bib0015","doi-asserted-by":"crossref","first-page":"e0121071","DOI":"10.1371\/journal.pone.0121071","article-title":"Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)","volume":"10","author":"Cedr\u00e8s","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.lungcan.2020.02.006_bib0020","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2020.02.006_bib0025","doi-asserted-by":"crossref","first-page":"S292","DOI":"10.1016\/j.jtho.2016.11.300","article-title":"A phase 2 study of nivolumab in malignant pleural mesothelioma (NivoMes): with translational research (TR) biopies","volume":"12","author":"Quispel-Janssen","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2020.02.006_bib0030","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1016\/j.jtho.2017.03.015","article-title":"FISH analysis of crizotinib target genes ROS1\/ALK\/MET in malignant mesothelioma","volume":"12","author":"Salvi","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2020.02.006_bib0035","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jamaoncol.2017.2918","article-title":"Identification of ALK rearrangements in malignant peritoneal mesothelioma","volume":"4","author":"Hung","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.lungcan.2020.02.006_bib0040","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10585-015-9772-8","article-title":"Brain metastases in malignant pleural mesothelioma","volume":"33","author":"Yamagishi","year":"2016","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.lungcan.2020.02.006_bib0045","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11864-019-0613-x","article-title":"Use of immune checkpoint inhibitors in mesothelioma","volume":"20","author":"Forde","year":"2019","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.lungcan.2020.02.006_bib0050","doi-asserted-by":"crossref","first-page":"S339","DOI":"10.1016\/j.jtho.2018.08.277","article-title":"Phase II Trial of pembrolizumab (NCT02399371) in previously-treated malignant mesothelioma (MM): final analysis","volume":"13","author":"Desai","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2020.02.006_bib0055","doi-asserted-by":"crossref","first-page":"e1261241","DOI":"10.1080\/2162402X.2016.1261241","article-title":"Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma","volume":"6","author":"Marcq","year":"2016","journal-title":"Oncoimmunology."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220303020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220303020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:37:14Z","timestamp":1759235834000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500220303020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":11,"alternative-id":["S0169500220303020"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.02.006","relation":{},"ISSN":["0169-5002"],"issn-type":[{"type":"print","value":"0169-5002"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}